Bristol Myers Squibb Signs $15.2B Licensing Deal with China's Hengrui Pharma

Why It Matters

The BMS‑Hengrui pact signals a shift toward leveraging China’s rapid discovery engines, while Makary’s exit could delay critical FDA interactions, and Regenxbio’s data offers the first credible accelerated‑approval pathway for Duchenne patients.

Key Takeaways

• BMS signs $15.2B China licensing pact, $600M upfront.
• Deal leverages 50‑70% faster Chinese trial timelines.
• FDA commissioner Makary resigns, acting head lacks drug review experience.
• Regenxbio’s RGX‑202 shows 71% microdystrophin, 93% exceed 10% threshold.
• Biomarker‑function link opens accelerated approval path for Duchenne therapy.

Pulse Analysis

The $15.2 billion collaboration between Bristol Myers Squibb and Hengrui Pharma marks the largest single pharma‑China licensing deal of 2026. By securing exclusive ex‑China rights to four Hengrui oncology and hematology candidates and swapping four BMS immunology assets into China, BMS is betting on the 50‑70 % faster clinical trial filing speed that Chinese research institutions claim. This model treats Chinese discovery as an outsourced pipeline engine rather than a competitive threat, echoing recent moves by Pfizer and Merck and potentially reshaping global R&D allocation as big pharma seeks to accelerate time‑to‑market.

Marty Makary’s abrupt resignation adds a new layer of volatility to an already turbulent FDA. With acting commissioner Kyle Diamantas coming from a food‑safety background, drug‑review processes may experience delays, especially for Type B meetings and PDUFA decisions slated for the summer. Companies in the midst of regulatory review now face uncertainty about feedback timing, prompting boardrooms to reassess risk buffers and contingency plans. Industry observers are watching for the next permanent commissioner, as the choice will signal the administration’s stance on regulatory rigor versus speed.

Regenxbio’s RGX‑202 Phase 3 data could redefine the Duchenne muscular dystrophy landscape. The trial demonstrated a mean microdystrophin expression of 71 % and a 93 % success rate in achieving the 10 % biomarker threshold, while also linking expression levels to functional improvement on the North Star Ambulatory Assessment. This biomarker‑to‑function correlation, absent in prior gene‑therapy submissions, positions RGX‑202 for an accelerated‑approval pathway and offers clinicians a viable alternative to Sarepta’s Elevidys, which carries a boxed warning for liver injury. If approved, the therapy could capture a sizable share of a market desperate for safer, more effective options.

Deal Summary

On May 12, 2026, Bristol Myers Squibb announced a global strategic collaboration with Hengrui Pharma to license 13 early‑stage oncology, hematology and immunology assets. The deal includes $600 million upfront and up to $15.2 billion in total value, granting BMS exclusive ex‑China rights to four Hengrui assets and Hengrui rights to four BMS immunology assets, plus five joint programs. The agreement is slated to close in Q3 2026 pending antitrust clearance.